⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27686718 | 0.77 | — | — | |
| Fluoride SCHEMBL27699158 | 0.74 | — | — | |
| Malonic Acid SCHEMBL23831 | 0.74 | LDHA (1.00) | — | |
| Malonic Acid SCHEMBL336 | 0.74 | — | — | |
| Malonic Acid SCHEMBL28221810 | 0.74 | LDHA (1.00) | — | |
| Malonic Acid SCHEMBL1332405 | 0.74 | — | — | |
| Malonic Acid SCHEMBL3358611 | 0.74 | — | — | |
| Malonic Acid SCHEMBL1332554 | 0.74 | — | — | |
| Malonic Acid SCHEMBL1332587 | 0.74 | — | — | |
| Malonic Acid SCHEMBL28859996 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020255017-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND DIHYDROPYRIMIDINE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | claimed |
| EP-3114128-B1 | NOVEL 6-FUSED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2019-01-02 | — | — | EP | claimed |
| US-10081627-B2 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2018-09-25 | — | — | US | claimed |
| EP-3114128-A1 | NOVEL 6-FUSED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2017-01-11 | — | — | EP | claimed |
| US-20160083383-A1 | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-03-24 | — | — | US | claimed |
| US-9233978-B2 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-01-12 | — | — | US | claimed |
| WO-2015132276-A1 | NOVEL 6-FUSED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2015-09-11 | — | — | WO | claimed |
| US-20150252057-A1 | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-09-10 | — | — | US | claimed |
| WO-2020255017-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND DIHYDROPYRIMIDINE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | disclosed |
| US-20200062753-A1 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2020-02-27 | — | — | US | disclosed |
| US-10428069-B2 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2019-10-01 | — | — | US | disclosed |
| EP-3114128-B1 | NOVEL 6-FUSED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2019-01-02 | — | — | EP | disclosed |
| US-20180370969-A1 | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2018-12-27 | — | — | US | disclosed |
| US-10081627-B2 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2018-09-25 | — | — | US | disclosed |
| US-20020165264-A1 | Aminal diones as potassium channel openers | ABBOTT LABORATORIES | 2002-11-07 | — | — | US | disclosed |
| US-20020147230-A1 | Aminal Diones as potassium channel openers | ABBOTT LABORATORIES | 2002-10-10 | — | — | US | disclosed |
| WO-2002062761-A1 | AMINAL DIONES AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2002-08-15 | — | — | WO | disclosed |
| EP-1198456-A2 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2002-04-24 | — | — | EP | disclosed |
| US-20020028836-A1 | Potassium channel openers | ABBVIE INC. | 2002-03-07 | — | — | US | disclosed |
| WO-2001009096-A2 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2001-02-08 | — | — | WO | disclosed |